Scott Dahlbeck
Founder bei KIROMIC BIOPHARMA, INC.
Vermögen: 40 806 $ am 31.03.2024
Profil
Scott Dahlbeck is the founder and currently holds the position of Chief of Staff at Kiromic Biopharma, Inc., a company he founded in 2006.
He is also the founder and currently holds the position of President & Chief Medical Officer at Kiromic, Inc., a company he founded in 2013.
Dr. Dahlbeck has a doctorate degree from the University of Nebraska Medical Center and The University of Texas Health Science Center at Houston.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KIROMIC BIOPHARMA, INC.
1,11% | 21.03.2024 | 14 318 ( 1,11% ) | 40 806 $ | 31.03.2024 |
Aktive Positionen von Scott Dahlbeck
| Unternehmen | Position | Beginn |
|---|---|---|
| KIROMIC BIOPHARMA, INC. | Founder | 06.08.2006 |
Kiromic, Inc.
 Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Founder | 01.01.2013 |
Ausbildung von Scott Dahlbeck
| University of Nebraska Medical Center | Doctorate Degree |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kiromic, Inc.
Kiromic, Inc. Medical/Nursing ServicesHealth Services Kiromic, Inc. is a biotech company that has discovered a breakthrough technology called the Diamond Artificial Intelligence platform. It serves as the foundation for Kiromic’s new drug discoveries through novel target identification. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck in 2013 and is headquartered in Houston, TX. | Health Services |
